Stockscreener 앱 받기
1.16
3.33%
-0.04
시간 외 거래:
1.22
0.06
+5.17%
Biomea Fusion Inc 주식(BMEA)의 최신 뉴스
Biomea Fusion Inc. Q1 2026 Earnings: EPS Beat on Cost Discipline as Biotech Advances PipelinePost-Announcement Reaction - newsline.com
[Form 4] Biomea Fusion, Inc. Insider Trading Activity - Stock Titan
Biomea Fusion (BMEA) director granted 196,299 stock options at $1.15 exercise price - Stock Titan
Biomea Fusion (BMEA) director Ray Sumita granted 196,299 stock options - Stock Titan
Biomea Fusion (BMEA) director receives 173,711-share stock option grant at $1.15 - Stock Titan
Citi Maintains Biomea Fusion(BMEA.US) With Buy Rating, Maintains Target Price $7 - Moomoo
Biomea Fusion (NASDAQ: BMEA) details 2026 director and auditor votes - Stock Titan
BMEA: Directors and auditors were approved by majority vote, with results to be filed with the SEC - TradingView
BMEA: All proposals, including director elections and auditor ratification, were approved - TradingView
Piper Sandler Maintains Biomea Fusion(BMEA.US) With Buy Rating, Maintains Target Price $7 - Moomoo
Biomea Fusion, Inc. (BMEA) Presents at American Diabetes Association (ADA) 86th Scientific SessionsSlideshow - Seeking Alpha
BMEA Q1 2026 Earnings: EPS Beat on Controlled Spending Overshadowed by Pipeline ConcernsAnalyst Drop Coverage - newsline.com
Biomea Fusion shows promising diabetes and obesity drug data, expands Phase I study for weight loss therapy. - Pluang
Biomea Fusion Presents Promising Clinical Data for Icovamenib and Expands Phase I Study of BMF-650 at ADA 2026 - Quiver Quantitative
Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association ('ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study - The Manila Times
Biomea Fusion Says Icovamenib Data Show Muscle Preservation And Fat Reduction In Obesity And Diabetes - TradingView
New diabetes pills show insulin gains and weight-loss potential at ADA - Stock Titan
BMEA: Phase II diabetes trials for a novel menin inhibitor target non-chronic, restorative therapy - TradingView
symbol__ Stock Quote Price and Forecast - CNN
Biomea Fusion to study icovamenib with semaglutide for weight loss - Investing.com UK
Icovamenib GLP-1 therapy combination evaluated in Biomea Fusion academic study - Traders Union
Biomea Fusion Announces Research Collaboration with University of Leicester to Evaluate Icovamenib in Combination with Semaglutide in Obesity - Investing News Network
Biomea Fusion to study icovamenib with semaglutide for weight loss By Investing.com - Investing.com South Africa
Biomea Fusion Announces Research Collaboration with - GlobeNewswire
Biomea Fusion icovamenib abstracts chosen for late-breaking poster presentations at diabetes conference - Traders Union
Biomea Fusion Q1 2026 Earnings: EPS Beats Estimates Despite No RevenueReturn On Assets - newsline.com
Biomea Fusion (BMEA) Holds Steady at $1.38, Testing Support as Traders Weigh Next MoveIsland Reversal - newsline.com
Biomea Fusion advances COVALENT-211 and COVALENT-212 research in type 2 diabetes - Traders Union
BMEA Q1 2026 Earnings: Narrower-than-Expected Loss Highlights Progress in Clinical PipelineGuidance Accuracy Score - newsline.com
Biomea Fusion (BMEA) Stages a Rebound: Testing Key Resistance After a +3.65% GainDaily Profile - thelegaladvocate.com
Biomea Fusion Shares Surge Over 6% as BMEA Tests Key ResistanceRisk Reward Setups - newsline.com
Biomea Fusion Q1 2026 Earnings: Narrowed Loss per Share Exceeds Expectations as Pipeline Progress Drives Stock UptickEarnings Quality Score - thelegaladvocate.com
BMEA Stock Price, Quote & Chart | BIOMEA FUSION INC (NASDAQ:BMEA) - ChartMill
Biomea Fusion, Inc.Common Stock (NQ: BMEA - FinancialContent
Oppenheimer Keeps Their Buy Rating on Biomea Fusion (BMEA) - The Globe and Mail
Oppenheimer Maintains Biomea Fusion(BMEA.US) With Buy Rating, Maintains Target Price $9 - Moomoo
Piper Sandler Maintains Biomea Fusion(BMEA.US) With Buy Rating, Raises Target Price to $7 - Moomoo
Biomea Fusion to Participate at Upcoming Investor Conferences - The Manila Times
Analyst Reiterates Buy on Biomea Fusion, Maintains $4 Price Target Amid Advancing Metabolic Pipeline - TipRanks
Biomea Fusion completes Icovamenib chronic tox studies and posts 52-week follow-up in diabetes pipeline - Traders Union
Biomea Fusion Inc (NASDAQ:BMEA) Q1 2026 Earnings Beat and Pipeline Progress Drive Cautious Optimism - ChartMill
Biomea Fusion Reports First Quarter 2026 Financial Results and Corporate Highlights - Investing News Network
BIOMEA FUSION ($BMEA) Releases Q1 2026 Earnings, Stock Rises - Quiver Quantitative
Biomea Fusion 4Q Loss/Shr 17c >BMEA - Moomoo
Biomea Fusion Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Biomea Fusion, Inc. Q1 2026: Net loss $(12.4)M, EPS $(0.17) — 10-Q Summary - TradingView
Biomea Fusion Q1 net loss narrows as expenses fall - TradingView
Biomea Fusion (BMEA) trims Q1 2026 loss but flags cash runway only into early 2027 - Stock Titan
Biomea Fusion, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Biomea Fusion (Nasdaq: BMEA) cuts Q1 2026 loss while advancing diabetes and obesity pipeline - Stock Titan
Biomea diabetes drug shows 52% C-peptide boost at 12 weeks - Stock Titan
BIOMEA FUSION ($BMEA) Releases Q1 2026 Earnings, Stock Rises | BMEA Stock News - Quiver Quantitative
BMEA.O Technical Analysis & Stock Price Forecast - Intellectia AI
BMEA Technical Analysis | Trend, Signals & Chart Patterns | BIOMEA FUSION INC (NASDAQ:BMEA) - ChartMill
Icovamenib boosts C-peptide secretion in 52-week diabetes trial - Traders Union
This Applied Materials Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Sahm
1.27%
1.43%
자본화:
|
볼륨(24시간):